Therapeutic plasma exchange for immune-mediated neurological diseases
Official title: Evaluation of Therapeutic Plasma Exchange for Immune-Mediated Neurological Diseases in a Sample of Egyptian Patients: An Experience at Al-Azhar University Hospitals
Run by Al-Azhar University · NCT07197099 · Data updated 2026-11-12
This project will see if therapeutic plasma exchange helps people in Egypt with immune-mediated neurological conditions such as Guillain-Barré syndrome, myasthenia gravis, CIDP, and multiple sclerosis.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Al-Azhar University Academic / other |
| Locations | 1 site (Cairo) |
| Status | Recruiting |
| Started | January 1, 2025 |
| Main results expected | October 30, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | November 18, 2025 |
| Trial ID | NCT07197099 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients of any age treated at Al-Azhar University Hospitals in Cairo who have an immune-mediated neurological disorder and meet ASFA criteria for TPE as first- or second-line therapy.
✕Probably not a fit
Patients with contraindications to TPE, those with non-neurological disorders, or those who fail to complete the prescribed five or more TPE sessions are unlikely to gain benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational, single-center project at Al-Azhar University Hospitals in Cairo collecting outcomes from patients who receive therapeutic plasma exchange (TPE) for immune-mediated neurological diseases. Adults and children who meet ASFA guidelines for TPE as first- or second-line therapy, including new and relapse cases, are included and followed for clinical response rates and functional improvement. Patients with contraindications to TPE or who do not complete at least five exchange sessions are excluded. The report will compare response and safety data to published experience to inform local practice.
Why it matters
Potential benefit: If successful, the findings could confirm benefit and inform how TPE is used and monitored for patients with neuroimmune disorders in Egyptian clinical settings.
How similar studies have gone: Multiple decades of prior studies have shown that TPE can benefit conditions like myasthenia gravis, Guillain-Barré syndrome, and CIDP, so this work adds local outcome data rather than testing a novel therapy.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. All neurological patients irrespective of age who will undergo TPE. 2.All new and relapse cases that meet the ASFA guidelines and where TPE is the first and/or second line of therapy Exclusion Criteria: * 1\. Individuals with contraindications to therapeutic plasma exchange, such as hemodynamic unstable, hypocalcaemia, allergy to fresh frozen plasma or albumin. 2.Patients who will undergo fewer than five cycles of TPE and not complete the procedure. 3.Patients with non-neurological disorders.
Where it's running
-
Al-Azhar University Hospitals
Cairo, Egypt Recruiting
Study contacts
- Study coordinator: Wajdi Hamid Eisay, MD
- Email: wajdyessa91@gmail.com
- Phone: 00218911103885
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CNCT19 CAR‑T treatment for relapsed or refractory antibody-mediated neurological autoimmune diseases
This trial will test whether a single CNCT19 CAR‑T cell injection is safe and can help adults (18–75) with relapsed or treatment‑resistant antibody‑mediated neurological autoimmune diseases.
-
GT719 injection for recurrent or refractory antibody-mediated neurological autoimmune disease
This trial will try an experimental cell therapy called GT719 in adults with recurrent or treatment-resistant antibody-mediated neurological autoimmune diseases to see if it is safe and may help disease activity.
-
Transabdominal vs. Transvaginal Ultrasound in high-risk pregnancies during early weeks
This study tests whether transabdominal ultrasound can visualize fetal structures as well as transvaginal ultrasound in high-risk singleton pregnancies between 9 and 13+6 weeks.
-
Ultrasound-Guided PRP Injections for Nerve Regeneration in Traumatic Peripheral Nerve Injury
This study tests whether ultrasound-guided platelet-rich plasma injections can help nerve regeneration in adults with traumatic peripheral nerve injuries.
-
Dual Trigger vs HCG Trigger for Final Maturation in Normal Responders
In normal responders undergoing ICSI cycles, this study tests whether using a dual trigger (GnRH agonist plus hCG) improves outcomes compared with the standard hCG trigger.
-
Criteria-based Rehabilitation After Tibial Fracture Fixation
This trial tests a structured, criteria-driven rehabilitation plan against usual physiotherapy after tibial fracture surgery to see if it improves leg function.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.